At advanced stages, the oncogenic function of DKK3 is instead mediated by IL6‐JAK‐STAT3 signaling, a well‐established driver of PDAC progression, promoting tumor cell proliferation, invasion, and resistance to therapy.[35, 36] Targeting this pathway may therefore offer therapeutic potential for DKK3‐positive tumors. The gene discussed is STAT3; the disease is neoplasm.